Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2002
Business Overview: Aastrom is a development-stage biotechnology company focused on human cell therapy products and devices. Its core platform is the AastromReplicell™ System, designed for the ex vivo production of therapeutic cells. Key product areas include Tissue Repair Cells (e.g., SC-I for stem cell therapy, OC-I for bone restoration) and Therapeutic Cells for Immunotherapy (e.g., DC-I and DCV-I kits for dendritic cell production). The company has obtained CE Mark approvals for several products, enabling sales in Europe, but requires FDA approval for U.S. commercialization.
Key Financial Metrics
| Metric | Year Ended June 30, 2002 | Year Ended June 30, 2001 |
|---|---|---|
| Total Revenues | $877,000 | $899,000 |
| Net Loss | $(7,939,000) | $(5,926,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.19) | $(0.17) |
| Cash, Cash Equivalents & Short-Term Investments | $9,605,000 | $10,659,000 |
| Working Capital | $10,597,000 | $10,715,000 |
| Accumulated Deficit | $(93,797,000) | $(85,858,000) |
Revenue Composition (2002): Grants accounted for $797,000 (91% of total revenue). Product sales and rentals were $80,000. Research and development agreements contributed $0 in 2002 (compared to $2,020,000 in the cumulative inception-to-date column, but $0 in the specific 2002 column of the selected financial data table).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 2.4% from $899,000 in 2001 to $877,000 in 2002, primarily due to a slight decrease in grant revenues ($814,000 to $797,000) and product sales ($85,000 to $80,000).
- Increased Operating Loss: The net loss widened by $2.01 million (34% increase) to $7.94 million. This was driven by a $1.05 million increase in Selling, General, and Administrative (SG&A) expenses due to expanded marketing activities in Europe, and a $0.45 million increase in Research and Development (R&D) expenses.
- Inventory Charges: Cost of product sales increased significantly to $202,000 in 2002 from $13,000 in 2001. This increase is attributed to a provision recorded for obsolete and excess inventory of the AastromReplicell™ System.
- Liquidity: Cash and short-term investments decreased by $1.05 million to $9.6 million, reflecting net cash used in operating activities of $8.75 million, partially offset by $7.85 million in proceeds from equity sales.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Outlook: Management expects available cash and interest income to fund planned activities into the first quarter of fiscal year 2004. However, the company anticipates needing additional funding prior to the end of the second quarter of fiscal year 2003. Failure to secure funding may result in substantial reductions in operations.
- Profitability: The company does not expect to generate positive cash flows from operations for at least the next several years. It has never been profitable and expects to incur significant losses until substantial product sales commence.
- Regulatory Risks: Commercialization in the U.S. is contingent upon FDA approval (PMA or BLA). The regulatory pathway for cell therapy products is uncertain. Delays or failures in clinical trials could prevent market entry.
- Supply Chain Risks: The company relies on third-party manufacturers. A key supplier, Moll Industries (Mid-State Plastics), filed for Chapter 11 bankruptcy in September 2002. Additionally, the manufacturing agreement with Plexus Corporation is set to terminate in February 2004, requiring a new supplier agreement.
- Stock Listing Risk: The company's stock price has traded below the $1.00 minimum bid price required for Nasdaq listing. Failure to regain compliance by February 24, 2003, could result in delisting.
- Market Risks: The company faces competition from established manual cell culture techniques and other biotechnology firms. Changes in reimbursement policies by third-party payors could limit market acceptance.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure financing before Q2 FY2003 to avoid operational curtailment.
- Supplier Stability: Confirm the status of the new manufacturing agreement to replace Plexus (terminating Feb 2004) and the impact of Moll Industries' bankruptcy on component supply.
- Regulatory Milestones: Monitor progress of Phase III-type clinical trials in the U.S. and the timeline for FDA Pre-Market Approval (PMA) or Biologic License Application (BLA).
- European Commercialization: Assess the actual revenue generation from CE Mark-approved products (SC-I, DC-I, DCV-I) in Europe, as current sales remain minimal.
- Inventory Valuation: Review the adequacy of the $202,000 reserve for obsolete inventory given the limited sales history and potential for further write-downs.